TITLE
Recommendation to authorize City Manager, or designee, to execute an agreement, and any subsequent amendments, with the State of California Department of Public Health, to receive and expend grant funding in an estimated amount of $25,200, to provide HIV Pre-Exposure Prophylaxis Assistance Program services, for the period January 1, 2018 through December 31, 2021. (Citywide)
DISCUSSION
In 2012, the first biomedical HIV prevention intervention for HIV negative individuals was implemented with the approval of the Food and Drug Administration (FDA) of the drug Truvada for use as Pre-Exposure Prophylaxis (PrEP). PrEP uses an HIV prevention prescription medication (Truvada) prescribed to people who do not have HIV, but are at substantial risk of contracting HIV. PrEP, as a biomedical prevention intervention, has been proven safe and effective in reducing HIV infection in people who are at high-risk of acquiring HIV by up to 92 percent when taken consistently.
The Department of Health and Human Services (Health Department) HIV Care Clinic’s medical providers have nearly five years of experience in providing biomedical HIV prevention services as co-investigators of a multi-year study led by the California Collaborative Treatment Group (CCTG), sponsored by the California Research Program (CHRP) and the Centers for Disease Control (CDC), as well as a previously executed contract to provide biomedical PrEP services through the County of Los Angeles Department of Public Health (LADPH).
The PrEP Assistance Program (PrEP-AP) is administered by the California Department of Public Health to subsidize certain costs of medication for the prevention of HIV infection and other related medical services for eligible individuals. The purpose of PrEP-AP is to help reduce new HIV infection among high-risk populations in California.
Through this agreement, the Health Department will participate as a clinical provider in the PrEP-AP Provider Network, to provide access to PrEP...
Click here for full text